Ultragenyx Pharma (RARE) Misses Q1 EPS by 6c

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.35), $0.06 worse than the analyst estimate of ($1.29).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says
• Bernstein SocGen on Oracle (ORCL): 'Next catalyst is FAM'